Adaptive Biotechnologies Stock Price, News & Analysis

Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotech company focused on adaptive immune system applications, has scheduled its Q2 2025 financial results announcement for August 5, 2025 after market close.

The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can access the live webcast through the company's website investor section, with a replay available within 24 hours after the event.

Adaptive Biotechnologies (NASDAQ: ADPT) has announced a strategic integration of its clonoSEQ® test for measurable residual disease (MRD) assessment into Flatiron Health's OncoEMR® platform. The integration provides streamlined access to MRD testing for over 4,500 clinicians across 1,000 community-based cancer care locations in the United States.

The integration, effective July 1, 2025, enables healthcare providers to order and review clonoSEQ MRD testing results directly within the Electronic Medical Record system. This development aims to improve testing workflows and provide real-time insights into patient disease status, particularly for blood cancer patients. The clonoSEQ test helps detect small numbers of cancer cells that may remain during and after treatment, serving as a key predictor of patient outcomes.

Adaptive Biotechnologies (ADPT) announced that its clonoSEQ test for measurable residual disease (MRD) assessment will be featured in 30 scientific presentations at ASCO and EHA 2025 conferences. The presentations include 14 oral presentations showcasing new data supporting clonoSEQ's clinical utility in multiple myeloma and chronic lymphocytic leukemia. Key highlights include the MIDAS phase 3 study of 718 patients demonstrating MRD-guided therapy in multiple myeloma, the ADVANCE phase 2 study with 306 patients showing MRD assessment impact, and the VENETOSTOP trial reporting MRD-guided therapy duration in CLL. Notable studies also showcase clonoSEQ's role in evaluating quadruplet regimens' efficacy in multiple myeloma, including the IsKia, PERSEUS, and DREAMM-8 trials, which demonstrated improved outcomes and higher MRD negativity rates with various treatment combinations.

Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company focused on adaptive immune system genetics, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. The company's management will engage in a fireside chat on June 11th at 5:40 a.m. PT / 8:40 a.m. ET. Investors and interested parties can access both live and archived webcasts of the presentation through the company's website investor section at www.adaptivebiotech.com.

Adaptive Biotechnologies (ADPT) reported strong Q1 2025 financial results with total revenue of $52.4 million, up 25% year-over-year. The company's MRD business, contributing 83% of revenue, grew 34% to $43.7 million, driven by a 36% increase in clonoSEQ test volume to 23,117 tests. Operating expenses decreased 9% to $82.0 million, and net loss improved to $29.8 million from $47.5 million in Q1 2024. The company raised its 2025 MRD revenue guidance to $180-190 million while reducing operating expense guidance to $335-345 million and cash burn target to $50-60 million. Cash position remained strong at $232.8 million as of March 31, 2025.

Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company focused on translating adaptive immune system genetics into clinical products, has scheduled its Q1 2025 financial results announcement for May 1, 2025, after market close.

The company will host a conference call and webcast at 1:30 PM Pacific Time / 4:30 PM Eastern Time on the same day. Investors can access the live audio webcast through the company's website investor section, with a replay available within 24 hours after the event.

Adaptive Biotechnologies (Nasdaq: ADPT) has secured expanded Medicare coverage for its clonoSEQ® test in mantle cell lymphoma (MCL) surveillance. The coverage now includes single time point testing to monitor disease recurrence in patients during treatment-free remission.

Under the expanded coverage by Palmetto GBA, patients who have completed treatment can receive clonoSEQ testing every six months for up to five years during treatment-free remission, followed by annual testing until disease recurrence. The test pricing is set at $2,007 per test under the Clinical Laboratory Fee Schedule.

MCL, affecting approximately 4,000 new cases annually in the United States, is the first clonoSEQ indication to receive this coverage determination. The test is performed at Adaptive's CLIA-certified lab in Seattle and has received approval from New York State's Clinical Laboratory Evaluation Program.

Adaptive Biotechnologies (NASDAQ: ADPT) has launched an enhanced version of its clonoSEQ assay for measuring residual disease (MRD) in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA. The upgraded assay delivers a 7-fold increase in sensitivity while maintaining high specificity to minimize false positives.

The enhanced version received approval from New York State's Clinical Lab Evaluation Program (CLEP) and is the only DLBCL MRD assay available for clinical use with Medicare coverage. Since securing Medicare coverage in July 2022, clonoSEQ has been used to test over 2,800 DLBCL patients and was utilized by more than 640 providers in 2024.

DLBCL, affecting over 18,000 new patients annually, is the most common form of non-Hodgkin lymphoma, representing one-third of NHL cases. With 30-40% of patients experiencing relapse, the enhanced MRD testing capabilities help doctors assess treatment response and detect early cancer recurrence signs.

Adaptive Biotechnologies (ADPT) reported Q4 and full year 2024 financial results, showing mixed performance. Q4 revenue reached $47.5 million (+4% YoY), with MRD business contributing 85% of revenue and growing 31% YoY to $40.1 million. Full-year revenue was $179.0 million (+5% YoY), with MRD revenue up 42% to $145.5 million.

The company's clonoSEQ test volume increased 34% to 20,945 tests in Q4 2024, with 76,105 tests delivered in 2024 (+35% YoY). Medicare increased the Clinical Laboratory Fee Schedule rate for clonoSEQ by 17% to $2,007 per test.

Q4 net loss improved to $33.7 million from $69.5 million in Q4 2023. Full-year 2024 net loss was $159.6 million, compared to $225.3 million in 2023. Cash position stood at $256.0 million as of December 31, 2024.

For 2025, ADPT expects MRD business revenue between $175-185 million and total operating expenses of $340-350 million, with projected cash burn of $60-70 million.